More recently, methylated septin 9 (SEPT9) gene, the biomarker used in the first blood-based test commercialized for the early detection of colorectal carcinoma, has demonstrated high accuracy (area under the receiver operating curve, AURC, of 0.94) to diagnose HCC in two independent cohorts [94] and to predict long-term survival of HCC patients [95]. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.